Advanced search
Start date
Betweenand

Therapeutic and toxicological effects of OncoTherad (MRB-CFI-1) immunotherapy in patients with BCG-refractory or relapsed non-muscle invasive bladder cancer

Grant number:20/03419-6
Support Opportunities:Regular Research Grants
Start date: July 01, 2020
End date: June 30, 2022
Field of knowledge:Biological Sciences - Morphology - Anatomy
Principal Investigator:Wagner José Fávaro
Grantee:Wagner José Fávaro
Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
City of the host institution:Campinas
Associated researchers:Athanase Billis ; João Carlos Cardoso Alonso ; Nelson Eduardo Duran Caballero

Abstract

Bladder cancer (BC) represents the second most common malignant disease of the urinary tract, and one of the neoplasms that have the highest costs for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on surgical treatment using transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to reduce recurrence and prevent tumor progression. However, the use of BCG is associated with side effects of varying intensities, from mild irritative symptoms to severe systemic reaction, which contributes to the interruption of treatment, in addition to presenting a post-treatment recurrence rate of up to 30%. The surgical option, partial or total cystectomy, is often associated with high rates of morbidity and mortality. In addition, for some patients, cystectomy is not an available option due to the presence of concomitant comorbidities. In Brazil, the manufacture and distribution of the OncoBCG vaccine suffers from constant interruptions. The lack of the OncoBCG vaccine can negatively impact the treatment of patients with bladder cancer. Thus, the development of new therapeutic modalities that prevent the progression of the disease, allow the preservation of the organ and the quality of life of patients and, finally, provide an option for those who are ineligible for cystectomy, is of fundamental importance. Considering the importance of developing drugs that can be administered intravesically and that act as modulators of the immune system, our research group developed a nanostructured synthetic compound with antitumor and immunological properties, called MRB-CFI-1 (Biological Response Modifier - Inorganic Phosphate Complex 1), or OncoTherad. The preclinical and clinical-veterinary studies of our group showed that in the treatment of chemically induced CBNMI in rodents and spontaneous in dogs, animals treated with OncoTherad showed significant inhibition of tumor progression in 70% - 80% of cases. In addition, our studies demonstrated that intravesical immunotherapy with OncoTherad led to distinct activation of the innate immune system mediated by TLRs 2 and 4, resulting in an increase in the signaling pathway for interferon, which is related to the greater effectiveness of this nanocomposite in the treatment of NMIBC compared to BCG treatment. Thus, the aims of this study are to evaluate the therapeutic effects of OncoTherad immunotherapy in patients with BCG-refractory or relapsed NMIBC, through analyzes of pathological complete response, relapse-free survival and progression, duration of response and time to disease recurrence during the 24-month follow-up. Moreover, this study aims to investigate the cellular mechanisms triggered by this therapy, as well as its possible local and systemic toxic effects. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (13)
(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)
ALONSO, J. C. C.; MACIEL, M. C.; FERRARI, H. A.; GONCALVES, J. M.; SASAKI, B. R. S.; CINTRA, A. A.; DURAN, N.; BILLIS, A.; FAVARO, W. J.; IOP PUBLISHING. Safety and Efficacy of OncoTherad Nano-immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer. Journal of Physics: Conference Series, v. 1953, p. 10-pg., . (18/10052-1, 20/03419-6)
REIS, SABRINA KAREN; RABELO SOCCA, EDUARDO AUGUSTO; DE SOUZA, BIANCA RIBEIRO; GENARO, SANDRA CRISTINA; DURAN, NELSON; FAVARO, WAGNER JOSE. Effects of combined OncoTherad immunotherapy and probiotic supplementation on modulating the chronic inflammatory process in colorectal carcinogenesis. TISSUE & CELL, v. 75, p. 13-pg., . (20/03419-6)
ALONSO, JOAO CARLOS CARDOSO; DE SOUZA, BIANCA RIBEIRO; REIS, IANNY BRUM; CAMARGO, GABRIELA CARDOSO DE ARRUDA; DE OLIVEIRA, GABRIELA; SALMAZO, MARIA IZABEL DE BARROS FRAZAO; GONCALVES, JULIANA MATTOSO; ROSTON, JOSE RONALDO DE CASTRO; CARIA, PAULO HENRIQUE FERREIRA; SANTOS, ANDRE DA SILVA; et al. OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v. 24, n. 24, p. 30-pg., . (18/10052-1, 20/03419-6)
REIS, IANNY BRUM; SOARES TIBO, LUIZ HENRIQUE; DE SOUZA, BIANCA RIBEIRO; DURAN, NELSON; FAVARO, WAGNER JOSE. OncoTherad(R) is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v. N/A, p. 12-pg., . (18/10052-1, 20/03419-6)
FAVARO, W. J.; ALONSO, J. C. C.; DE SOUZA, B. R.; REIS, I. B.; GONCALVES, J. M.; DECKMANN, A. C.; OLIVEIRA, G.; DIAS, Q. C.; DURAN, N.. New synthetic nano-immunotherapy (OncoTherad?) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property. TISSUE & CELL, v. 80, p. 15-pg., . (18/10052-1, 20/03419-6)
FERREIRA, FABIO F.; PEREIRA, ALINE P. C.; REIS, IANNY B.; SASAKI, BIANCA R. S.; FAVARO, WAGNER J.; DURAN, NELSON. Quantitative phase analysis of commercial ammonium phosphates by PXRD for application in biological systems. Powder Diffraction, v. N/A, p. 12-pg., . (18/10052-1, 20/03419-6, 21/03640-7)
ROSTON, JOSE RONALDO DE CASTRO; REIS, IANNY BRUM; LUZO, ANGELA CRISTINA MALHEIROS; ROSTON, MILENA OLIVIERI; DURAN, NELSON; FAVARO, WAGNER JOSE. Evaluation of the tissue repair process and immunomodulatory action of Platelet-Rich Plasma (PRP) in the treatment of abdominal stretch marks. TISSUE & CELL, v. 83, p. 15-pg., . (18/10052-1, 20/03419-6)
REIS, SABRINA KAREN; SOCCA, EDUARDO AUGUSTO RABELO; DE SOUZA, BIANCA RIBEIRO; GENARO, SANDRA CRISTINA; DURAN, NELSON; FAVARO, WAGNER JOSE. Effects of probiotic supplementation on chronic inflammatory process modulation in colorectal carcinogenesis. TISSUE & CELL, v. 87, p. 12-pg., . (20/03419-6)
ALONSO, JOAO CARLOS CARDOSO; GONSALVES, JULIANA MATTOSO; CAMARGO, GABRIELA CARDOSO DE ARRUDA; DE OLIVEIRA, GABRIELA; DA SILVA SANTOS, ANDRE; CINTRA, ADRIANO ANGELO; GUIMARAES, FABIO; DE FREITAS, LEANDRO LUIZ LOPES; BOTTENE, MARTIM CORREA; LESTINGI, JEAN FELIPE PRODOCIMO; et al. Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-γ profiling. TISSUE & CELL, v. 98, p. 12-pg., . (18/10052-1, 23/15929-7, 22/15126-9, 22/09698-0, 23/08336-0, 20/03419-6, 22/09699-6)
ZAMBRANA, ANDRE B. R. M.; SANTOS, ANDRE DA SILVA; CAMARGO, GABRIELA CARDOSO DE ARRUDA; OLIVEIRA, GABRIELA; DE FREITAS, LEANDRO LUIZ LOPES; KOBARG, JORG; CINTRA, ADRIANO ANGELO; LESTINGI, JEAN FELIPE PRODOCIMO; BOTTENE, MARTIN; GUIMARAES, FABIO; et al. Immune and inflammatory profiling in bladder cancer: Insights into biomarkers and therapeutic strategies.. Journal of Clinical Oncology, v. 43, n. 5_SUPPL, p. 1-pg., . (20/03419-6, 22/09699-6, 23/15929-7, 22/15126-9, 18/10052-1, 22/09698-0)
SALMAZO, MARIA IZABEL DE BARROS FRAZA; ALONSO, JOAO CARLOS CARDOSO; CAMARGO, GABRIELA CARDOSO DE ARRUDA; DE OLIVEIRA, GABRIELA; SANTOS, ANDRE DA SILVA; AVILA, MONALIZA; ROBERTO, ISADORA MANZATO; DE FREITAS, LEANDRO LUIZ LOPES; BOTTENE, MARTIM CORREA; LESTINGI, JEAN FELIPE PRODOCIMO; et al. Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle invasive bladder cancer. TISSUE & CELL, v. 93, p. 11-pg., . (22/09698-0, 18/10052-1, 23/15929-7, 20/03419-6, 22/09699-6, 22/15126-9)
FAVARO, WAGNER JOSE; DE ARRUDA CAMARGO, GABRIELA CARDOSO; OLIVEIRA, GABRIELA; ROBERTO, ISADORA MANZATO; AVILA, MONALIZA; SANTOS, ANDRE DA SILVA; LOPES DE FREITAS, LEANDRO LUIZ; BILLIS, ATHANASE; CARDOSO ALONSO, JOAO CARLOS. Relevance of immune tumor microenvironment and its interaction with HABP4 and SERBP1 proteins in bladder cancer.. Journal of Clinical Oncology, v. 42, n. 16, p. 1-pg., . (18/10052-1, 20/03419-6)
CAMARGO, GABRIELA CARDOSO DE ARRUDA; OLIVEIRA, GABRIELA; SANTOS, BRUNA NAYARA SILVA; ROBERTO, ISADORA MANZATO; AVILA, MONALIZA; DE SOUZA, BIANCA RIBEIRO; ALONSO, JOAO CARLOS CARDOSO; DURAN, NELSON; FAVARO, WAGNER JOSE. Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases. MEDICAL ONCOLOGY, v. 41, n. 11, p. 16-pg., . (18/10052-1, 22/04796-3, 20/03419-6)